Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Total Non-Current Liabilities (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Total Non-Current Liabilities data on record, last reported at $5.9 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 0.72% year-over-year to $5.9 million; the TTM value through Sep 2025 reached $5.9 million, down 0.72%, while the annual FY2024 figure was $5.7 million, 21.57% down from the prior year.
  • Total Non-Current Liabilities reached $5.9 million in Q3 2025 per MBRX's latest filing, down from $8.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $8.2 million in Q2 2025 and bottomed at $3.4 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $5.7 million, with a median of $5.9 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: soared 81.39% in 2022, then plummeted 34.83% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $3.7 million in 2021, then skyrocketed by 39.86% to $5.2 million in 2022, then skyrocketed by 41.42% to $7.3 million in 2023, then dropped by 21.57% to $5.7 million in 2024, then grew by 3.9% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $5.9 million in Q3 2025, $8.2 million in Q2 2025, and $7.2 million in Q1 2025.